Stryker Corporation $SYK Holdings Boosted by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. increased its holdings in Stryker Corporation (NYSE:SYK) by 25.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,745 shares of the medical technology company’s stock after acquiring an additional 6,683 shares during the period. Oppenheimer & Co. Inc.’s holdings in Stryker were worth $9,018,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of SYK. Segment Wealth Management LLC lifted its stake in Stryker by 5.6% in the third quarter. Segment Wealth Management LLC now owns 59,971 shares of the medical technology company’s stock valued at $16,515,000 after acquiring an additional 3,198 shares during the last quarter. Verdence Capital Advisors LLC lifted its stake in Stryker by 103.6% in the 3rd quarter. Verdence Capital Advisors LLC now owns 28,206 shares of the medical technology company’s stock valued at $7,768,000 after acquiring an additional 14,355 shares in the last quarter. Noesis Capital Mangement Corp boosted its holdings in Stryker by 36.3% during the third quarter. Noesis Capital Mangement Corp now owns 104,945 shares of the medical technology company’s stock worth $28,901,000 after purchasing an additional 27,938 shares during the last quarter. Apollon Wealth Management LLC boosted its stake in shares of Stryker by 21.2% during the 3rd quarter. Apollon Wealth Management LLC now owns 11,156 shares of the medical technology company’s stock worth $3,072,000 after buying an additional 1,950 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC grew its stake in Stryker by 2.5% in the third quarter. Kingswood Wealth Advisors LLC now owns 2,285 shares of the medical technology company’s stock valued at $629,000 after purchasing an additional 56 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SYK. Raymond James Financial set a $370.00 target price on shares of Stryker in a report on Friday, July 31st. Wells Fargo & Company dropped their price target on Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a report on Wednesday, September 9th. UBS Group started coverage on Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target for the company. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, JPMorgan Chase & Co. lowered their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $369.00.

Insiders Place Their Bets

In other Stryker news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda Stryker sold 300,000 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 in the last 90 days. Company insiders own 4.60% of the company’s stock.

Stryker Price Performance

NYSE SYK opened at $301.59 on Wednesday. The firm has a 50-day moving average price of $294.70 and a two-hundred day moving average price of $325.45. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the business posted $3.13 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 14.93 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.